Announcements Trials
Browse Landscape

Status

No longer available 2Available 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 240Expanded_access 3Observational 2

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Carcinoma, Non-Small-Cell Lung 32Multiple Myeloma 26Neoplasms 25Recurrence 23Melanoma 19Leukemia, Myeloid, Acute 16Breast Neoplasms 15Prostatic Neoplasms 12Pancreatic Neoplasms 11Glioblastoma 11Sarcoma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lung Neoplasms 9Ovarian Neoplasms 8Lymphoma 8Glioma 8Colorectal Neoplasms 8Small Cell Lung Carcinoma 7Lymphoma, Large B-Cell, Diffuse 7Carcinoma, Renal Cell 7Lymphoma, Non-Hodgkin 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Gastrointestinal Stromal Tumors 6Cholangiocarcinoma 6Triple Negative Breast Neoplasms 5Stomach Neoplasms 5Neoplasm Metastasis 5Leukemia, Lymphocytic, Chronic, B-Cell 5Thyroid Neoplasms 4Lymphoma, Mantle-Cell 4

Interventions

pazopanib 1carotuximab 1Capecitabine 1Bevacizumab 1Axitinib 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Expanded_access × Solid Tumors × Clear all
NCT05982873 2026-02-06

Expanded Access to Telisotuzumab Adizutecan

AbbVie

Available
Other solid neoplasm

Solid Tumors

NCT05107193 2022-11-08

Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors)

Boehringer Ingelheim

No longer available
Other solid neoplasm

Solid Tumors

NCT02354612 2021-02-15

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

Tracon Pharmaceuticals Inc.

No longer available
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡